1,3-Butylene Glycol Product
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,521,328 | 1,3-Butylene Glycol Product In force · High confidence UsedRemaining | Daicel Corporation | In force | High confidence | ||
| US 12,458,571 | 1,3-Butylene Glycol Product In force · High confidence | Daicel Corporation | In force | High confidence | ||
| US 12,728,083 | 1,3-Butylene Glycol Product In force · High confidence | Daicel Corporation | In force | High confidence | ||
| Application 19/364,623 | 1,3-Butylene Glycol Product Pending Not granted | Daicel Corporation | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Daicel Corporation.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.